Fawzi F Abu Rous, MD, discusses evolving strategies for HER2 and MET testing in non–small cell lung cancer.
Fawzi F Abu Rous, MD
Advertisement
Fawzi F Abu Rous, MD, is a thoracic medical oncologist at Henry Ford Health.
Articles by Fawzi F Abu Rous, MD
Fawzi F Abu Rous, MD, discusses the need for reliable predictive biomarkers for therapeutic development in squamous cell carcinoma of the lung.
Advertisement
Latest Updated Articles
Dr Abu Rous on the Timing of HER2 and MET Testing in NSCLCPublished: August 22nd 2025 | Updated:
Dr Abu Rous on the Identification of Clinically Actionable Biomarkers in Squamous Cell Carcinoma of the LungPublished: April 14th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5